Insulin resistance and beta-cell dysfunction as therapeutic targets in type 2 diabetes.
Evans
A J
AJ
Diabetes and Endocrinology, Southampton General Hospital, Southampton SO16 6YD, UK.
Krentz
A J
AJ
D003920:Diabetes Mellitus / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy*; D015195:Drug Design; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism / Q000502:physiology*; D007333:Insulin Resistance; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000378:metabolism / Q000503:physiopathology*; D009765:Obesity / Q000503:physiopathology
D007004:Hypoglycemic Agents; D007328:Insulin